Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2012

Q-Biologicals Enters Animal Health Collaboration

  • Q-Biologicals signed an agreement with Virbac, a French veterinary company. Q-Biologicals will collaborate with Virbac in the development of technologies and production processes suitable for Virbac biological projects in animal health. With this agreement, Virbac prolongs the existing relationship with Q-Biologicals and will be able to use the company’s experience in the production of recombinant proteins, viruses, and microbial live cells.

    “The signing of a five-year framework agreement with one of the leading veterinary companies is a strong recognition of Q-Biologicals’ knowledge and practical experience as contract manufacturing company in the field of biologicals,” says Annie Van Broekhoven, Q-Biologicals’ CEO.

    Q-Biologicals produces recombinant proteins derived from microbial and eukaryotic systems, and conducts purification for research purposes, toxicological studies, and clinical trials, including formulation development and stress stability studies. The company also has experience in the manufacturing of viruses and living cells for vaccine purposes.

    Earlier this year, Q-Biologicals entered a service framework agreement with Bayer CropScience to produce and purify recombinant proteins for Bayer.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »